Sym 015

Drug Profile

Sym 015

Alternative Names: Sym-015

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Symphogen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Jun 2016 SUREtechnology Platform and SURE CHO-M Cell Line™ licensed to Symphogen
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Mar 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT02648724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top